Loading…
INMB
Inmune Bio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 45782T105
$2.33-2.92%Price as of Aug 29, 18:36 UTC · updated once a day, after the close
Key metrics
- Market cap
- $64.67M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.62
- ROE
- -74.82%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.90
- 52-week high
- $2.50
- 52-week low
- $1.09
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -89.0% over 5Y.
today you would have $104.53▼ -89.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.56 | $4.67 | $11.26 | $6.34 | $10.20 | $17.22 | $5.80 | |
| P/S | 1164.5x | 829.5x | 7648.9x | 1322.4x | 304.2x | 1006.6x | 23376.4x | — |
| P/B | 2.6x | 1.8x | 3.3x | 5.5x | 1.9x | 2.3x | 6.6x | 2.6x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BOLDBoundless Bio, Inc. | $2.83 | — | 1.0x | — | -67.86% | $64.38M |
| NNOXNano-X Imaging Ltd. | $0.83 | — | 0.5x | — | -50.12% | $65.2M |
| HYFTMindWalk Holdings Corp. | $1.39 | — | 7.6x | — | -85.38% | $65.31M |
| RNTXRein Therapeutics, Inc. | $0.76 |
About the company
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
- 21
- Boca Raton, United States
Company description provided by Yahoo Finance.